Celcuity Inc. (CELC) - Long-Term Debt to Capital

Celcuity Inc. (CELC) is a biopharmaceutical company developing personalized cellular tests to identify tumor defects. This chart illustrates the price action of the asset, which has a debt ratio of 0.00. The business relies on robotic platforms for high-precision sample analysis, while diagnostic reliability is ensured by the rapid air transport of biomaterials to laboratories under strict temperature control.

The financial stability of Celcuity Inc. (CELC) depends on the balance between oncology drug development costs and the volume of equity. This metric compares long-term loans with maturities exceeding one year against net assets, determining the business's degree of reliance on debt financing. An analysis of the company's long-term debt-to-equity ratio allows for an assessment of bankruptcy risk or the readiness for aggressive growth prior to entering the premium diagnostics market.